ACD-856 (NeuroRestore)
Cognitive · Pan-Trk positive allosteric modulator
Tier C+
What this is
AlzeCure Pharma (Sweden) lead clinical asset. Novel mechanism — small-molecule pan-Trk allosteric kinase potentiator. Mechanistically distinct from anti-amyloid mAbs and cholinesterase inhibitors — directly relevant given the Cochrane 2026 finding that the entire anti-amyloid class produces only trivial cognitive benefit (see Anti-amyloid mAbs row). Phase 1 SAD safety/PK (Hagberg 2024 Eur J Clin Pharmacol) and Phase 1 MAD with QEEG biomarker (JPAD 2023) were the key clinical anchors; trial NCT05077501. €2.5M EU European Innovation Council grant awarded 2025 for the planned Phase 2a in AD patients. Other indications in preclinical/IND-enabling: depressive disorders, sleep disorders, TBI, Parkinson's-related cognitive impairment. **NOT a usable intervention as of May 2026** — Phase 2 efficacy not yet read out, not commercially available, no legitimate compounding pathway. Included because biohacker readers tracking the AD pipeline will encounter it, and Trk-PAM is a novel-enough mechanism to merit a watchlist row. Next decision-relevant event: Phase 2a efficacy readout (likely 2027-2028). Practical note: "ACD-856" sometimes appears in research-chemical channels — there is no legitimate sourcing of this compound for human use outside of registered trials.
Mechanism
Small-molecule triazinetrione that allosterically potentiates the intracellular kinase domain of all three neurotrophin receptors (pan-Trk: TrkA EC50=382 nM; TrkB=295 nM; TrkC=33 nM); amplifies endogenous BDNF/NGF signaling rather than mimicking it; downstream effects on neurite outgrowth; synaptic plasticity; BDNF expression; and anti-inflammatory pathways; orally bioavailable with CNS penetration; proposed disease-modifying via neurotrophin restoration — distinct from cholinesterase inhibitors and anti-amyloid antibodies
Dose & route
10-90 mg/day PO range tested in Phase 1 MAD; Phase 2a dose TBD
Citations
- https://www.alzforum.org/therapeutics/acd856
- https://link.springer.com/article/10.1007/s00228-024-03645-1
- https://link.springer.com/article/10.14283/jpad.2023.89
- https://www.mdpi.com/1422-0067/24/13/11159
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11357672/
- https://clinicaltrials.gov/study/NCT05077501
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.